Literature DB >> 21435749

[Evaluation of a prototype real-time PCR assay for the separate detection of human papilloma virus genotypes 16 and 18 and other high risk human papillomavirus in cervical cancer screening].

María Luisa Mateos1, Jesús Chacón de Antonio, Mario Rodríguez-Domínguez, Itziar Sanz, María Dolores Rubio.   

Abstract

BACKGROUND: It has recently been confirmed that detection of DNA of human papilloma virus (HPV) is more useful than cytology in the screening for cervical cancer, especially if genotypes 16 and 18 are identified. Cobas 4800 is an automated system that detects 14 high risk HPV genotypes: genotypes 16 and 18 separately and 12 other high-risk genotypes pooled.
OBJECTIVES: The aim of this study is to compare the performance of the cobas 4800 HPV test against the hybrid capture 2 (HC2) and particularly in women in whom>CIN2 lesions are detected. PATIENTS AND METHODS: Aliquots from 412 cervical specimens have been studied with three different assays, real time PCR (cobas 4800), Linear Array HPV test, and HC2. Cytological and histological results were also available.
RESULTS: There was good agreement between the cobas 4800 and HC2 results in 376 of the 412 women (kappa 0.85). Where there was not good agreement, low-risk HPV genotypes were detected by linear array in the majority of samples positive by HC2 and negative by the cobas 4800. Sensitivity and specificity for detecting>CIN2 lesions were 92.5 and 44%, respectively, by cobas 4800, and 88 and 51% by hybrid capture.
CONCLUSIONS: In this evaluation the cobas 4800 HPV test was shown to have a similar performance to the HC2 test. However HC2 was less specific due to cross reactivity with low risk genotypes, mainly genotype 53. Cobas 4800 is very reliable in the detection of high-risk genotypes, with the advantage of simultaneously providing information regarding genotype16 and 18 infections.
Copyright © 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21435749     DOI: 10.1016/j.eimc.2011.01.007

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  6 in total

1.  Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix.

Authors:  Simon Grandjean Lapierre; Philippe Sauthier; Marie-Hélène Mayrand; Simon Dufresne; Patrick Petignat; Diane Provencher; Pierre Drouin; Philippe Gauthier; Marie-Josée Dupuis; Bertrand Michon; Stéphan Ouellet; Rachid Hadjeres; Alex Ferenczy; Eduardo L Franco; François Coutlée
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

2.  Clinical validation of the cobas 4800 HPV test for cervical screening purposes.

Authors:  D A M Heideman; A T Hesselink; J Berkhof; F van Kemenade; W J G Melchers; N Fransen Daalmeijer; M Verkuijten; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

Review 3.  Potential Role of E4 Protein in Human Papillomavirus Screening: a Review

Authors:  Aidy Irman Yajid; Mohd Azali Zakariah; Anani Aila Mat Zin; Nor Hayati Othman
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

Review 4.  Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers.

Authors:  Maryam Soheili; Hossein Keyvani; Marzieh Soheili; Sherko Nasseri
Journal:  Med J Islam Repub Iran       Date:  2021-05-22

Review 5.  A review of methods for detect human Papillomavirus infection.

Authors:  André L P Abreu; Raquel P Souza; Fabrícia Gimenes; Marcia E L Consolaro
Journal:  Virol J       Date:  2012-11-06       Impact factor: 4.099

6.  Prevalence of high-risk human papillomavirus by cobas 4800 HPV test in urban Peru.

Authors:  Ricardo Iwasaki; Felipe Galvez-Philpott; Javier Arias-Stella; Javier Arias-Stella
Journal:  Braz J Infect Dis       Date:  2014-05-15       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.